Antidepressants And Pregnancy: Weighing The Risks And Benefits

Taking antidepressants during pregnancy is a difficult decision for many women. While there is evidence that antidepressants can negatively affect the developing foetus, untreated depression can also have harmful effects on both the mother and the baby.

Antidepressants are known to cross the placental and blood-brain barrier and pass into breast milk, potentially affecting the functional development of the foetus's brain. However, discontinuing antidepressants during pregnancy may also not be the right approach, as untreated mental illness poses risks to a developing foetus. Women who are depressed are less likely to receive adequate prenatal care and more likely to engage in unhealthy or dangerous behaviours, like smoking and substance use.

Some studies have linked antidepressant use during pregnancy to an increased risk of preterm birth, low birth weight, respiratory distress, persistent pulmonary hypertension in the newborn, birth defects, and neonatal withdrawal symptoms. However, other studies have found no association between antidepressant use and these outcomes.

The decision to continue or discontinue antidepressants during pregnancy should be made in consultation with a doctor, weighing the risks and benefits unique to each individual.

Antidepressants and birth defects

Selective Serotonin Reuptake Inhibitors (SSRIs) are the most commonly used antidepressants during pregnancy. Some studies have linked SSRIs to an increased risk of birth defects, including heart defects, abdominal wall defects, respiratory issues, cleft lip and palate, and persistent pulmonary hypertension of the newborn (PPHN). However, other studies have found no increased risk of major congenital malformations associated with SSRIs. The American College of Obstetricians and Gynecologists recommends avoiding paroxetine during pregnancy due to its potential link to cardiac defects.

Tricyclic antidepressants (TCAs), such as amitriptyline and nortriptyline, have not been found to increase the risk of major congenital malformations. However, they may increase the risk of preterm birth, low birth weight, respiratory distress, hypoglycemia, low Apgar score, and convulsions.

Venlafaxine, a selective norepinephrine reuptake inhibitor (SNRI), has been associated with the highest proportion of elevated birth defect risks. It has been linked to heart and neural tube defects, gastroschisis, and oral cleft defects.

While there are some risks associated with antidepressant use during pregnancy, untreated mental illness can also have negative consequences for both the mother and the fetus. Depression during pregnancy can lead to increased risk of stillbirth, premature birth, low birth weight, poor bonding after birth, and an increased risk of depression and anxiety in the child later in life. Therefore, it is crucial for pregnant women to discuss their medication use and mental health with their doctors to make informed decisions about their treatment options.

Antidepressants and miscarriage

Several studies have found an association between antidepressant use and an increased risk of miscarriage. For example, a 2010 study published in the Canadian Medical Association Journal found that 6% of women who had miscarried had filled at least one prescription for an antidepressant during pregnancy, compared to 3% of those who did not miscarry. After adjusting for potential confounders, the researchers determined that the risk of miscarriage in antidepressant users was 68% higher than in non-users. Another study, published in Epidemiology in 2016, found that antidepressant use in the first trimester was associated with an increased risk of miscarriage when compared to non-depressed or depressed women who were not exposed to antidepressants.

However, it is important to note that the link between antidepressant use and miscarriage may be influenced by other factors, such as maternal depression. Some studies suggest that it is the underlying depression, rather than the use of antidepressants, that contributes to the increased risk of miscarriage. Additionally, the type of antidepressant and the dosage may also play a role. For instance, a study published in CMAJ in 2010 found that the use of selective serotonin reuptake inhibitors (SSRIs) alone was associated with a 61% increased risk of miscarriage, while the use of serotonin-norepinephrine reuptake inhibitors (SNRIs) alone was associated with a 211% increased risk. Furthermore, the combined use of different classes of antidepressants further increased the risk.

On the other hand, some studies suggest that antidepressant use may not significantly increase the risk of miscarriage. A meta-analysis published in JAMA Psychiatry, which analyzed data from 11 studies, found no significant association between antidepressant exposure and the risk of spontaneous abortion. Similarly, a study published in Obstetrics and Gynecology in 2014 found that women who discontinued SSRI treatment before pregnancy had a similar risk of miscarriage as those who continued taking SSRIs.

While the research on this topic is ongoing, it is clear that both antidepressant use and untreated depression during pregnancy carry potential risks. It is crucial for women to carefully weigh the risks and benefits of taking antidepressants during pregnancy in consultation with their healthcare providers.

Antidepressants and premature birth

Several studies have examined the relationship between antidepressant use during pregnancy and preterm birth, with findings suggesting an increased risk of preterm birth for women taking antidepressants. A meta-analysis of 41 studies found that the pooled adjusted odds ratios for preterm birth were 1.53 (1.40-1.66) for any antidepressant use during pregnancy and 1.96 (1.62-2.38) for use in the third trimester. The risk was higher for antidepressant use in the second and third trimesters compared to the first trimester.

Confounding Factors

It is important to note that the association between antidepressant use and preterm birth may be influenced by confounding factors such as depression severity. Some studies have tried to control for this by comparing women with depression who did and did not use antidepressants during pregnancy, and most of these studies still found an increased risk of preterm birth with antidepressant use. However, it is difficult to completely rule out the potential impact of depression severity on preterm birth risk.

Clinical Implications

The findings suggest that pregnant women taking antidepressants should be counselled about the potential risk of preterm birth, especially if they are taking antidepressants in the second or third trimester. However, it is also important to consider the risks of untreated depression, which can have negative consequences for both the mother and the baby. Therefore, the decision to continue or discontinue antidepressants during pregnancy should be made on a case-by-case basis, weighing the risks and benefits of each option.

Antidepressants and breastfeeding

Breastfeeding mothers with depression face a dilemma: to take antidepressants and risk exposing their infant to the drug through breast milk, or to stop taking medication and risk the adverse effects of untreated depression.

Risks of untreated depression

Deciding to stop taking antidepressants during breastfeeding is a difficult decision that should be made in consultation with a doctor. Untreated depression can have harmful effects on both the mother and the baby. It can impair a mother's ability to take care of herself and her child, leading to poor maternal health, increased risk of preeclampsia and eclampsia, and difficulties in the mother-child relationship. It can also cause functional impairment in the mother and increase the risk of psychopathology in children.

Risks of taking antidepressants

Antidepressants can pass into breast milk and may cause adverse effects in the infant. However, the risks are generally low, and the benefits of breastfeeding are well-documented. The decision to breastfeed while taking medication should be made on a case-by-case basis, taking into consideration factors such as the mother's mental health history, the infant's age and health, and the mother's breastfeeding preferences.

All antidepressants pass into breast milk to some degree, but the concentrations vary. Sertraline and paroxetine are considered safer options as they have been shown to have low or undetectable levels in infant serum. Fluoxetine and citalopram are also considered safe but may cause mild side effects like drowsiness and irritability. Other antidepressants such as venlafaxine, mirtazapine, and bupropion have been associated with more serious side effects like withdrawal symptoms and seizures, but the evidence is limited.

Monitoring and reducing risks

Routine infant serum drug level monitoring is not usually recommended unless there are signs of neonatal toxicity or if the mother is taking lithium, valproic acid, carbamazepine, or clozapine. To reduce the risk of exposing the infant to antidepressants, mothers can consider taking the daily drug dose in the evening to avoid breastfeeding during the peak concentration phase, or pumping and discarding breast milk. However, these strategies may not significantly reduce the already low exposure.

Antidepressants and neonatal withdrawal

Pregnant women taking antidepressants may worry about the effects on their babies. While there is evidence that antidepressants can cause neonatal withdrawal, the symptoms are usually mild and short-lived, disappearing within 48 hours and requiring no medical intervention. However, it is important to closely monitor newborns for any signs of withdrawal.

Symptoms of Neonatal Withdrawal

Babies exposed to antidepressants in utero may experience a range of withdrawal symptoms, including:

• Tremors
• Hypotonia
• Hypertonia
• Tachycardia
• Rapid breathing
• Respiratory distress
• Hypoglycemia (low blood sugar)
• Jitteriness or tremors
• Poor muscle tone
• Difficulty crying or feeding
• Increased irritability or agitation
• Excess sleepiness
• High blood pressure in the lungs

Risk Factors

The risk of neonatal withdrawal is higher for babies exposed to antidepressants late in pregnancy. Additionally, certain types of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), are associated with a higher risk of withdrawal symptoms.

Management and Prevention

To prevent neonatal withdrawal, it is recommended that mothers discontinue antidepressant use before and during the early stages of pregnancy if possible. However, this decision should be made in consultation with a doctor, as untreated mental illness during pregnancy can also pose risks to both the mother and the baby. In some cases, the benefits of continuing antidepressant medication may outweigh the risks of withdrawal.

If a mother continues taking antidepressants during pregnancy, it is recommended that she gives birth in a hospital and stays for a minimum of 48 hours after delivery to ensure the baby can be closely monitored for any signs of withdrawal.

Frequently asked questions